trending Market Intelligence /marketintelligence/en/news-insights/trending/qSI2mll4STnaZr9VBAQvdA2 content esgSubNav
In This List

US FDA approves new dose of Allergan/Ironwood constipation drug

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


US FDA approves new dose of Allergan/Ironwood constipation drug

The U.S. FDA approved a 72 microgram dose of Ironwood Pharmaceuticals Inc. and Allergan PLC's LINZESS for the treatment of chronic idiopathic constipation in adults.

The new dose is expected to be available in the first quarter of 2017. Approval of the new dose was based on the results of a phase 3 trial of 1,223 adults with the disease.

LINZESS is now FDA-approved in three dosages: 290 mcg for patients with irritable bowel syndrome with constipation, and 145 mcg and 72 mcg for adults with chronic idiopathic constipation.